The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) closed the day trading at $62.56 up 0.95% from the previous closing price of $61.97. In other words, the price has increased by $0.95 from its previous closing price. On the day, 1.19 million shares were traded. BMRN stock price reached its highest trading level at $62.7 during the session, while it also had its lowest trading level at $61.61.
Ratios:
For a better understanding of BMRN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 37.27. For the most recent quarter (mrq), Quick Ratio is recorded 2.62 and its Current Ratio is at 4.27. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on November 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $95.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 12 ’24 when Guyer Charles Greg sold 5,278 shares for $66.37 per share. The transaction valued at 350,324 led to the insider holds 68,909 shares of the business.
Guyer Charles Greg bought 5,278 shares of BMRN for $350,324 on Nov 12 ’24. On Aug 13 ’24, another insider, Burkhart Erin, who serves as the GVP, Chief Accounting Officer of the company, sold 714 shares for $90.00 each. As a result, the insider received 64,260 and left with 14,449 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 11922873344 and an Enterprise Value of 11595116544. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.67, and their Forward P/E ratio for the next fiscal year is 19.66. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.71. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.34 while its Price-to-Book (P/B) ratio in mrq is 2.20. Its current Enterprise Value per Revenue stands at 4.212 whereas that against EBITDA is 27.213.
Stock Price History:
Over the past 52 weeks, BMRN has reached a high of $99.56, while it has fallen to a 52-week low of $61.15. The 50-Day Moving Average of the stock is -9.44%, while the 200-Day Moving Average is calculated to be -22.96%.
Shares Statistics:
Over the past 3-months, BMRN traded about 1.79M shares per day on average, while over the past 10 days, BMRN traded about 1419240 shares per day. A total of 188.60M shares are outstanding, with a floating share count of 188.20M. Insiders hold about 1.25% of the company’s shares, while institutions hold 96.60% stake in the company. Shares short for BMRN as of 1730332800 were 5378964 with a Short Ratio of 3.00, compared to 1727654400 on 5280095. Therefore, it implies a Short% of Shares Outstanding of 5378964 and a Short% of Float of 2.8399997999999997.
